Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone marrow transplantation in multiple myeloma.

R L Schlossman1, K C Anderson

  • 1Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Current Opinion in Oncology
|April 3, 1999
PubMed
Summary

High-dose therapy followed by stem cell transplantation shows promise for multiple myeloma but faces challenges. Strategies are being developed to overcome toxicity and minimal residual disease for improved patient survival.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A high-throughput platform for biophysical antibody developability assessment to enable AI/ML model training.

mAbs·2025
Same author

Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.

Leukemia·2024
Same author

Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.

Seminars in hematology·2023
Same author

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Leukemia·2019
Same author

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Leukemia·2018
Same author

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Leukemia·2017

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • High-dose therapy with hematopoietic stem cell transplantation (HSCT) yields high response rates in multiple myeloma.
  • Despite high response rates, multiple myeloma patients often relapse, with limited cures due to transplant-related toxicities and persistent minimal residual disease.

Purpose of the Study:

  • To review current strategies for improving outcomes in multiple myeloma patients undergoing HSCT.
  • To address major obstacles including allograft toxicity, tumor cell contamination in autografts, and minimal residual disease.

Main Methods:

  • Investigating methods to reduce allograft toxicity and enhance allogeneic immune responses against multiple myeloma.
  • Exploring improved ablative regimens and tumor cell purging techniques for autografts.

Related Experiment Videos

  • Examining strategies to boost autologous anti-multiple myeloma immunity post-transplantation.

    • Main Results:

    • Current HSCT approaches demonstrate high initial responses but are limited by relapse and toxicity.
    • Persistent minimal residual disease remains a significant barrier to achieving a cure.
    • Ongoing research focuses on enhancing graft-versus-myeloma effects and reducing treatment-related complications.

    Conclusions:

    • Improving HSCT for multiple myeloma requires addressing toxicity, tumor cell contamination, and minimal residual disease.
    • Enhancing allogeneic immunity and autologous immune responses post-transplantation are key areas for future research.
    • Novel strategies aim to improve overall and event-free survival in multiple myeloma patients.